Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
Gynecol Oncol
    August 2022
  1. KUMAR A, Wang C, Sheedy SP, McCauley BM, et al
    Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
    Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00492.
    >> Share

  2. SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
    Corrigendum to "Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer" [Gynecologic Oncology, Volume 165, Issue 2, May 2022, Pages 270-280].
    Gynecol Oncol. 2022;166:370-371.
    >> Share

    July 2022
  3. HOARE JI, Hockings H, Saxena J, Silva VL, et al
    A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
    Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00511.
    >> Share

  4. JOLY F, Fabbro M, Berton D, Lequesne J, et al
    Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00426.
    >> Share

  5. LIANG MI, Simons JL, Herbey I, Wall JA, et al
    Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00493.
    >> Share

  6. CHASE DM, Marin MR, Backes F, Han S, et al
    Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
    Gynecol Oncol. 2022 Jul 15. pii: S0090-8258(22)00432.
    >> Share

  7. HARE CJ, Crangle C, McGarragle K, Ferguson SE, et al
    Change in cancer-related fatigue over time predict health-related quality of life in ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00433.
    >> Share

  8. PITIYARACHCHI O, Friedlander M, Java JJ, Chan JK, et al
    What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (>/=10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemothera
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00436.
    >> Share

  9. PIEDIMONTE S, Bernardini MQ, Ding A, Laframboise S, et al
    Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
    Gynecol Oncol. 2022 Jul 9. pii: S0090-8258(22)00430.
    >> Share

  10. CADOO K, Simpkins F, Mathews C, Liu YL, et al
    Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    Gynecol Oncol. 2022 Jul 5. pii: S0090-8258(22)00421.
    >> Share

  11. TSENG JH, Bristow RE
    Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles.
    Gynecol Oncol. 2022;166:5-7.
    >> Share

  12. HANDLEY KF, Sood AK, Molin GZD, Westin SN, et al
    Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.
    Gynecol Oncol. 2022;166:50-56.
    >> Share

  13. O'CEARBHAILL RE, Perez-Fidalgo JA, Monk BJ, Tusquets I, et al
    Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
    Gynecol Oncol. 2022;166:36-43.
    >> Share

    June 2022
  14. WALL JA, Lipking K, Smith HJ, Huh WK, et al
    Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
    Gynecol Oncol. 2022 Jun 28. pii: S0090-8258(22)00420.
    >> Share

  15. KEUNECKE C, Kulbe H, Dreher F, Taube ET, et al
    Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
    Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00414.
    >> Share

  16. KIM NR, Lee AJ, Yang EJ, So KA, et al
    Minimally invasive surgery versus open surgery in high-risk histologic endometrial cancer patients: A meta-analysis.
    Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00404.
    >> Share

  17. CAMPBELL R, Costa DSJ, Stockler MR, Lee YC, et al
    Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
    Gynecol Oncol. 2022 Jun 16. pii: S0090-8258(22)00335.
    >> Share

  18. HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
    OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
    Gynecol Oncol. 2022 Jun 8. pii: S0090-8258(22)00331.
    >> Share

  19. LOF P, van de Vrie R, Korse CM, van Gent MDJM, et al
    Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?
    Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00336.
    >> Share

  20. NASIOUDIS D, Mastroyannis SA, Ko EM, Haggerty AF, et al
    Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database.
    Gynecol Oncol. 2022 Jun 3. pii: S0090-8258(22)00314.
    >> Share

  21. GERSHENSON DM, Sun CC, Westin SN, Eyada M, et al
    The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
    Gynecol Oncol. 2022;165:560-567.
    >> Share

  22. HOU X, Zhai Y, Hu K, Liu CJ, et al
    Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
    Gynecol Oncol. 2022;165:552-559.
    >> Share

    May 2022
  23. BROEKMAN KE, van der Aa MA, Nijman HW, Jalving M, et al
    End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis.
    Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00258.
    >> Share

  24. TYMON-ROSARIO JR, Manara P, Manavella DD, Bellone S, et al
    Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Gynecol Oncol. 2022 May 19. pii: S0090-8258(22)00305.
    >> Share

  25. WANG CC, Al-Rubaye R, Tran V, Montemorano L, et al
    Mechanical and oral antibiotic bowel preparation in ovarian cancer debulking: Are we lowering or just trading surgical complications?
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00307.
    >> Share

  26. HINCHCLIFF E, Westin SN, Herzog TJ
    State of the science: Contemporary front-line treatment of advanced ovarian cancer.
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00275.
    >> Share

  27. ANGELES MA, Hernandez A, Perez-Benavente A, Cabarrou B, et al
    The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2022 May 11. pii: S0090-8258(22)00278.
    >> Share

  28. GUIDA F, Dioun S, Fagotti A, Melamed A, et al
    Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2022 May 9. pii: S0090-8258(22)00218.
    >> Share

    April 2022
  29. WILHITE AM, Baca Y, Xiu J, Paladugu R, et al
    Molecular profiles of endometrial cancer tumors among Black patients.
    Gynecol Oncol. 2022 Apr 27. pii: S0090-8258(22)00255.
    >> Share

  30. FU Z, Taylor S, Modugno F
    Lifetime ovulations and epithelial ovarian cancer risk and survival: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Apr 23. pii: S0090-8258(22)00214.
    >> Share

  31. WANG D, Jia S, Jia C, Cao D, et al
    Oncological and reproductive outcomes after fertility-sparing surgery in patients with seromucinous borderline ovarian tumor: Results of a large retrospective study.
    Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00215.
    >> Share

  32. LOF P, Retel VP, Algera MD, van Gent MDJM, et al
    Clinical implementation of routine diagnostic laparoscopy to guide initial treatment in patients with advanced-stage epithelial ovarian cancer in Dutch clinical practice: Evaluation of support and a budget impact analysis.
    Gynecol Oncol. 2022 Apr 9. pii: S0090-8258(22)00210.
    >> Share

  33. GERSEKOWSKI K, Delahunty R, Alsop K, Goode EL, et al
    Germline BRCA variants, lifestyle and ovarian cancer survival.
    Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00202.
    >> Share

  34. NORPPA N, Staff S, Helminen M, Auranen A, et al
    Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center.
    Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00205.
    >> Share

  35. BIZZARRI N, Marchetti C, Conte C, Loverro M, et al
    The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
    Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00206.
    >> Share

  36. HENNO S, Jeanne C, Rouge TM, Genestie C, et al
    Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).
    Gynecol Oncol. 2022 Apr 4. pii: S0090-8258(22)00201.
    >> Share

  37. VAN DER PLOEG P, Uittenboogaard A, Bosch SL, van Diest PJ, et al
    Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium.
    Gynecol Oncol. 2022;165:114-120.
    >> Share

    March 2022
  38. MARINELLI LM, Kisiel JB, Slettedahl SW, Mahoney DW, et al
    Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00200.
    >> Share

  39. SIMILA-MAARALA J, Soovares P, Pasanen A, Ahvenainen T, et al
    TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00198.
    >> Share

  40. LIM H, In Shim J, Park SJ, Noh J, et al
    Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery.
    Gynecol Oncol. 2022 Mar 30. pii: S0090-8258(22)00196.
    >> Share

  41. STELTEN S, van Lonkhuijzen LRCW, Hartman YAW, van Driel WJ, et al
    Experiences, adherence and satisfaction with a combined exercise and dietary intervention for patients with ovarian cancer undergoing chemotherapy: A mixed-methods study.
    Gynecol Oncol. 2022 Mar 22. pii: S0090-8258(22)00182.
    >> Share

  42. SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
    Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2022 Mar 16. pii: S0090-8258(22)00176.
    >> Share

  43. MOUKARZEL LA, Ferrando L, Dopeso H, Stylianou A, et al
    Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.
    Gynecol Oncol. 2022 Mar 12. pii: S0090-8258(22)00141.
    >> Share

  44. HAWKINS GM, Burkett WC, McCoy AN, Nichols HB, et al
    Differences in the microbial profiles of early stage endometrial cancers between Black and White women.
    Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00142.
    >> Share

  45. CHALIF J, Yao M, Gruner M, Kuznicki M, et al
    Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2022 Mar 7. pii: S0090-8258(22)00065.
    >> Share

  46. SCHNARR KL, Seow H, Pond GR, Helpman L, et al
    The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers.
    Gynecol Oncol. 2022 Mar 2. pii: S0090-8258(22)00129.
    >> Share

    February 2022
  47. GOINS EC, Weber JM, Truong T, Moss HA, et al
    Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database.
    Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00069.
    >> Share

  48. FALCONE F, Malzoni M, Carnelli M, Cormio G, et al
    Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database.
    Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00128.
    >> Share

  49. MATSUO K, Chen L, Guo XM, Roman LD, et al
    Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study.
    Gynecol Oncol. 2022 Feb 25. pii: S0090-8258(22)00126.
    >> Share

  50. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    Corrigendum to "A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer" [Gynecologic Oncology 163 (2021) 481-489].
    Gynecol Oncol. 2022 Feb 23. pii: S0090-8258(22)00124.
    >> Share

  51. KIM YN, Kim JC, Chung YS, Park J, et al
    Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00091.
    >> Share

  52. LAFARGUE CJ, Handley KF, Fleming ND, Nick AM, et al
    Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00090.
    >> Share

  53. ALGERA MD, van Driel WJ, Slangen BFM, Kruitwagen RFPM, et al
    Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00123.
    >> Share

  54. VANDERSTICHELE A, Loverix L, Busschaert P, Van Nieuwenhuysen E, et al
    Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
    Gynecol Oncol. 2022 Feb 14. pii: S0090-8258(22)00073.
    >> Share

  55. PARK J, Kim SI, Jeong SY, Kim Y, et al
    Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    Gynecol Oncol. 2022 Feb 10. pii: S0090-8258(22)00086.
    >> Share

  56. WAGAR MK, Mojdehbakhsh RP, Godecker A, Rice LW, et al
    Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
    Gynecol Oncol. 2022 Feb 7. pii: S0090-8258(22)00071.
    >> Share

  57. LEMON LS, Orr B, Modugno F, Buckanovich RJ, et al
    Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?
    Gynecol Oncol. 2022 Feb 6. pii: S0090-8258(22)00049.
    >> Share

  58. JOLY F, Fabbro M, Follana P, Lequesne J, et al
    A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
    Gynecol Oncol. 2022 Feb 2. pii: S0090-8258(22)00048.
    >> Share

    January 2022
  59. TRILLSCH F, Mahner S, Ataseven B, Asher R, et al
    Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
    Gynecol Oncol. 2022 Jan 31. pii: S0090-8258(22)00050.
    >> Share

  60. RAIMONDO D, Raffone A, Zakhari A, Maletta M, et al
    The impact of hysterectomy on oncological outcomes in patients with borderline ovarian tumors: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jan 25. pii: S0090-8258(22)00046.
    >> Share

  61. COLOMBO N, Tomao F, Benedetti Panici P, Nicoletto MO, et al
    Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00023.
    >> Share

  62. XIA YY, Gronwald J, Karlan B, Lubinski J, et al
    Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00022.
    >> Share

  63. BOUCHARD-FORTIER G, Gien LT, Sutradhar R, Chan WC, et al
    Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00004.
    >> Share

  64. POVEDA A, Lheureux S, Colombo N, Cibula D, et al
    Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(21)01693.
    >> Share

  65. ZHANG J, Yu S, Li Q, Wang Q, et al
    Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in ovarian cancer.
    Gynecol Oncol. 2022 Jan 15. pii: S0090-8258(22)00018.
    >> Share

  66. FIEGL H, Hagenbuchner J, Kyvelidou C, Seeber B, et al
    Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroids.
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00009.
    >> Share

  67. WEINMANN S, Phillips S, Sweet K, Cosgrove CM, et al
    Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01695.
    >> Share

  68. LIN DI, Fine A, Danziger NA, Huang RSP, et al
    Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01698.
    >> Share

  69. SHALOWITZ DI, DeMari JA
    Defining the essential role of the gynecologic oncologist in rural ovarian cancer care delivery.
    Gynecol Oncol. 2022;164:1-2.
    >> Share

    December 2021
  70. CORRIGAN KL, Yoder A, De B, Lin L, et al
    Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis.
    Gynecol Oncol. 2021 Dec 30. pii: S0090-8258(21)01690.
    >> Share

  71. BEESLEY VL, Ross TL, King MT, Campbell R, et al
    Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01632.
    >> Share

  72. REIJNTJES B, van Suijlichem M, Woolderink JM, Bongers MY, et al
    Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial.
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01676.
    >> Share

  73. PHILP L, Alimena S, Ferris W, Saini A, et al
    Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer.
    Gynecol Oncol. 2021 Dec 22. pii: S0090-8258(21)01674.
    >> Share

  74. HARTER P, Mouret-Reynier MA, Pignata S, Cropet C, et al
    Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
    Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01673.
    >> Share

  75. MONK BJ, Smith G, Lima J, Long GH, et al
    Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
    Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01634.
    >> Share

  76. KO EM, Bekelman JE, Hicks-Courant K, Brensinger CM, et al
    Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers.
    Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01627.
    >> Share

  77. AGHAJANIAN C, Swisher EM, Okamoto A, Steffensen KD, et al
    Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
    Gynecol Oncol. 2021 Dec 17. pii: S0090-8258(21)01638.
    >> Share

  78. HA HI, Park EY, Eoh KJ, Lee YJ, et al
    Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
    Gynecol Oncol. 2021 Dec 16. pii: S0090-8258(21)01639.
    >> Share

  79. SWIFT BE, Maeda A, Bouchard-Fortier G
    Low incidence of venous thromboembolism after gynecologic oncology surgery: Who is at greatest risk?
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01637.
    >> Share

  80. ZHOU ZN, Chen L, Melamed A, St Clair CM, et al
    Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer.
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01631.
    >> Share

  81. SWISHER EM, Aghajanian C, O'Malley DM, Fleming GF, et al
    Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Gynecol Oncol. 2021 Dec 11. pii: S0090-8258(21)01630.
    >> Share

  82. HODGSON DR, Brown JS, Dearden SP, Lai Z, et al
    Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
    Gynecol Oncol. 2021;163:563-568.
    >> Share

    November 2021
  83. JOHN CS, Fong A, Alban R, Gillen J, et al
    Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
    Gynecol Oncol. 2021 Nov 30. pii: S0090-8258(21)01521.
    >> Share

  84. DUPONT NC, Enserro D, Brady MF, Moxley K, et al
    Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2021 Nov 29. pii: S0090-8258(21)01607.
    >> Share

  85. MOYA-ALARCON C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, et al
    Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
    Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01604.
    >> Share

  86. CIANCI S, Fedele C, Vizzielli G, Pasciuto T, et al
    Surgical outcomes of diaphragmatic resection during cytoreductive surgery for advanced gynecological ovarian neoplasia: A randomized single center clinical trial - DRAGON.
    Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01605.
    >> Share

  87. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Corrigendum to "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile" [Gynecologic Oncology 162 (2021) 686-693].
    Gynecol Oncol. 2021 Nov 19. pii: S0090-8258(21)01601.
    >> Share

  88. MATUSZEWSKA K, Ten Kortenaar S, Pereira M, Santry LA, et al
    Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01599.
    >> Share

  89. MATTHEWS BJ, Qureshi MM, Fiascone SJ, Nitschmann CC, et al
    Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer.
    Gynecol Oncol. 2021 Nov 13. pii: S0090-8258(21)01553.
    >> Share

  90. WEEKS KS, Lynch CF, West M, Carnahan R, et al
    Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01555.
    >> Share

  91. KHOJA L, Weber RP, Webb PM, Jordan SJ, et al
    Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01552.
    >> Share

  92. MANNING-GEIST BL, Gordhandas SB, Giri DD, Iasonos A, et al
    Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01551.
    >> Share

  93. FABER MT, Horsbol TA, Baandrup L, Dalton SO, et al
    Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996-2017.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01554.
    >> Share

    October 2021
  94. ROCCONI RP, Wilhite AM, Schambeau L, Scalici J, et al
    A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01527.
    >> Share

  95. CALO CA, Smith BQ, Dorayappan KDP, Saini U, et al
    Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01520.
    >> Share

  96. GOLDBERG RM, Kim SR, Fazelzad R, Li X, et al
    Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01524.
    >> Share

  97. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
    Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study.
    Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01525.
    >> Share

  98. SOOVARES P, Pasanen A, Simila-Maarala J, Butzow R, et al
    Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade.
    Gynecol Oncol. 2021 Oct 25. pii: S0090-8258(21)01522.
    >> Share

  99. WALTER A, Rocconi RP, Monk BJ, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01422.
    >> Share

  100. WITJES VM, van Bommel MHD, Ligtenberg MJL, Vos JR, et al
    Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01516.
    >> Share

  101. TREDAN O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al
    Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01402.
    >> Share

  102. HARRISON R, Zighelboim I, Cloven NG, Marcus JZ, et al
    Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01452.
    >> Share

  103. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01513.
    >> Share

  104. GERNIER F, Gompel A, Rousset-Jablonski C, Kalbacher E, et al
    Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.
    Gynecol Oncol. 2021 Oct 11. pii: S0090-8258(21)01419.
    >> Share

  105. KONECNY GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, et al
    Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 9. pii: S0090-8258(21)01413.
    >> Share

  106. LIU J, Burris H, Wang JS, Barroilhet L, et al
    An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2021 Oct 6. pii: S0090-8258(21)01403.
    >> Share

  107. SHAH PD, Wethington SL, Pagan C, Latif N, et al
    Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 4. pii: S0090-8258(21)01322.
    >> Share

  108. TEWARIE NMSB, van Driel WJ, van Ham M, Wouters MW, et al
    Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01392.
    >> Share

  109. CLAIR KH, Bristow RE
    The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers.
    Gynecol Oncol. 2021;163:3-4.
    >> Share

  110. ALHILLI MM, Rybicki L, Carr C, Yao M, et al
    Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01377.
    >> Share

    September 2021
  111. SWISHER EM, Kristeleit RS, Oza AM, Tinker AV, et al
    Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01329.
    >> Share

  112. HA HI, Cho SH, Lim J, Lee YJ, et al
    Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01383.
    >> Share

  113. AZZALINI E, Barbazza R, Stanta G, Giorda G, et al
    Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01382.
    >> Share

  114. LI JY, Park HS, Huang GS, Young MR, et al
    Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01391.
    >> Share

  115. BRYK S, Katuwal S, Haltia UM, Tapper J, et al
    Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study.
    Gynecol Oncol. 2021 Sep 28. pii: S0090-8258(21)01381.
    >> Share

  116. ATASEVEN B, Tripon D, Schwameis R, Harter P, et al
    Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01335.
    >> Share

  117. RESHKO LB, Gaskins JT, Rattani A, Farley AA, et al
    Patterns of care and outcomes of radiotherapy or hormone therapy in patients with medically inoperable endometrial adenocarcinoma.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01375.
    >> Share

  118. LEE SJ, Kim YH, Lee MY, Ko HS, et al
    Ultrasonographic evaluation of ovarian mass for predicting malignancy in pregnant women.
    Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01376.
    >> Share

  119. HUANG T, Townsend MK, Dood RL, Sood AK, et al
    Antihypertensive medication use and ovarian cancer survival.
    Gynecol Oncol. 2021 Sep 20. pii: S0090-8258(21)01378.
    >> Share

  120. WENZEL L, Huang HQ, Cella D, McKinney CO, et al
    Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
    Gynecol Oncol. 2021 Sep 18. pii: S0090-8258(21)01326.
    >> Share

  121. GAILLARD S, Oaknin A, Ray-Coquard I, Vergote I, et al
    Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
    Gynecol Oncol. 2021 Sep 11. pii: S0090-8258(21)01330.
    >> Share

  122. MOSS HA, Chen L, Hershman DL, Davidson B, et al
    Adherence to PARP inhibitor therapy among women with ovarian cancer.
    Gynecol Oncol. 2021 Sep 9. pii: S0090-8258(21)01323.
    >> Share

  123. WANG Z, Guo E, Yang B, Xiao R, et al
    Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer.
    Gynecol Oncol. 2021 Sep 7. pii: S0090-8258(21)01327.
    >> Share

  124. WERNER B, Yuwono N, Duggan J, Liu D, et al
    Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
    Gynecol Oncol. 2021;162:720-727.
    >> Share

  125. CAMPBELL R, King MT, Ross TL, Cohen PA, et al
    Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.
    Gynecol Oncol. 2021 Sep 1. pii: S0090-8258(21)01320.
    >> Share

    August 2021
  126. FUH KC, Bookman MA, Liu JF, Coleman RL, et al
    Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
    Gynecol Oncol. 2021 Aug 30. pii: S0090-8258(21)01318.
    >> Share

  127. STEENBEEK MP, van Bommel MHD, Harmsen MG, Hoogerbrugge N, et al
    Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
    Gynecol Oncol. 2021 Aug 26. pii: S0090-8258(21)01317.
    >> Share

  128. POZZAR RA, Xiong N, Hong F, Wright AA, et al
    Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer.
    Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)00652.
    >> Share

  129. EBINA Y, Yamagami W, Kobayashi Y, Tabata T, et al
    Clinicopathological characteristics and prognostic factors of ovarian granulosa cell tumors: A JSGO-JSOG joint study.
    Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)01310.
    >> Share

  130. TAMURA R, Yoshihara K, Matsuo K, Yachida N, et al
    Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01307.
    >> Share

  131. SOMASEGAR S, Weiss AS, Norquist BM, Khasnavis N, et al
    Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01315.
    >> Share

  132. D'AMORA P, Silva IDCG, Tewari KS, Bristow RE, et al
    Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis.
    Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)00646.
    >> Share

  133. D'ALESSANDRIS N, Travaglino A, Santoro A, Arciuolo D, et al
    TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
    Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)01309.
    >> Share

  134. COWAN M, Swetzig WM, Adorno-Cruz V, Pineda MJ, et al
    Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
    Gynecol Oncol. 2021 Aug 18. pii: S0090-8258(21)00650.
    >> Share

  135. BANERJEE SN, Tang M, O'Connell RL, Sjoquist K, et al
    A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
    Gynecol Oncol. 2021 Aug 16. pii: S0090-8258(21)00586.
    >> Share

  136. LUTGENDORF SK, Ramirez E, Schrepf A, Valentine MC, et al
    Rural residence is related to shorter survival in epithelial ovarian cancer patients.
    Gynecol Oncol. 2021 Aug 13. pii: S0090-8258(21)00601.
    >> Share

  137. PARK M, Lim J, Lee JA, Park HJ, et al
    Incidence and outcomes of malignant ovarian germ cell tumors in Korea, 1999-2017.
    Gynecol Oncol. 2021 Aug 12. pii: S0090-8258(21)00645.
    >> Share

  138. WETHINGTON SL, Wahner-Hendrickson AE, Swisher EM, Kaufmann SH, et al
    PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine.
    Gynecol Oncol. 2021 Aug 11. pii: S0090-8258(21)00647.
    >> Share

  139. WENTZENSEN N, O'Brien KM
    Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence.
    Gynecol Oncol. 2021 Aug 5. pii: S0090-8258(21)00598.
    >> Share

  140. COLOMBO N, Moore K, Scambia G, Oaknin A, et al
    Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
    Gynecol Oncol. 2021 Aug 2. pii: S0090-8258(21)00578.
    >> Share

  141. SALANI R, Liu JF
    The American Society of Clinical Oncology 2021 annual (virtual) meeting: A review and summary of selected abstracts.
    Gynecol Oncol. 2021;162:245-248.
    >> Share

  142. GROENEWEG JW, Roze JF, Peters EDJ, Sereno F, et al
    FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
    Gynecol Oncol. 2021;162:413-420.
    >> Share

    July 2021
  143. BANTIE L, Tadesse S, Likisa J, Yu M, et al
    Erratum to "A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer" [Gynecologic Oncology 159 (2020) 827-838].
    Gynecol Oncol. 2021 Jul 30. pii: S0090-8258(21)00580.
    >> Share

  144. VILLANUEVA C, Chang J, Ziogas A, Bristow RE, et al
    Ambient air pollution and ovarian cancer survival in California.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00602.
    >> Share

  145. NANEZ A, Stram DA, Garcia C, Powell CB, et al
    Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00600.
    >> Share

  146. LAZURKO C, Clark M, Pulman K, Lennox G, et al
    Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
    Gynecol Oncol. 2021 Jul 26. pii: S0090-8258(21)00589.
    >> Share

  147. BASARAN D, Boerner T, Suhner J, Sassine D, et al
    Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
    Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00592.
    >> Share

  148. MARCHETTI C, Rosati A, De Felice F, Boccia SM, et al
    Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis.
    Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00587.
    >> Share

  149. EOH KJ, Park EY, Chang YJ, Ha HI, et al
    The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jul 22. pii: S0090-8258(21)00590.
    >> Share

  150. MOSS HA, Perhanidis JA, Havrilesky LJ, Secord AA, et al
    Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2021 Jul 20. pii: S0090-8258(21)00588.
    >> Share

  151. CIBULA D, Rob L, Mallmann P, Knapp P, et al
    Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00533.
    >> Share

  152. DE NONNEVILLE A, Zemmour C, Frank S, Joly F, et al
    Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00581.
    >> Share

  153. ZENG H, Chen L, Zhang M, Luo Y, et al
    Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00577.
    >> Share

  154. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00531.
    >> Share

  155. GHONIEM K, Larish AM, Dinoi G, Zhou XC, et al
    Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study.
    Gynecol Oncol. 2021 Jul 14. pii: S0090-8258(21)00526.
    >> Share

  156. KURODA Y, Chiyoda T, Kawaida M, Nakamura K, et al
    ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00536.
    >> Share

  157. BACKES FJ, Wei L, Chen M, Hill K, et al
    Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00528.
    >> Share

  158. HERMENS M, van Altena AM, Bulten J, van Vliet HAAM, et al
    Increased incidence of ovarian cancer in both endometriosis and adenomyosis.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00535.
    >> Share

  159. HUFFMAN DL, Jayakrishnan TT, Shankar K, Peterson CE, et al
    Disparities in ovarian cancer treatment and overall survival according to race: An update.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00541.
    >> Share

  160. VAN DER PLOEG P, Uittenboogaard A, Thijs AMJ, Westgeest HM, et al
    The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00538.
    >> Share

  161. KIM SR, Malcolmson J, Li X, Bernardini MQ, et al
    The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00540.
    >> Share

  162. GRUNER M, Chambers LM, Yao M, Chichura A, et al
    Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00530.
    >> Share

  163. SULLIVAN MW, Philp L, Kanbergs AN, Safdar N, et al
    Lymph node assessment at the time of hysterectomy has limited clinical utility for patients with pre-cancerous endometrial lesions.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00534.
    >> Share

  164. GADDUCCI A, Multinu F, Cosio S, Carinelli S, et al
    Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00529.
    >> Share

  165. KRASNER CN, Campos SM, Young CL, Chadda KR, et al
    Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Jul 6. pii: S0090-8258(21)00532.
    >> Share

  166. HILLMAN RT, Lin DI, Lawson B, Gershenson DM, et al
    Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.
    Gynecol Oncol. 2021 Jul 5. pii: S0090-8258(21)00518.
    >> Share

    June 2021
  167. BENOIT L DR, Zerbib J Dr, Koual M Dr, Nguyen-Xuan HT Dr, et al
    What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?
    Gynecol Oncol. 2021 Jun 30. pii: S0090-8258(21)00521.
    >> Share

  168. SAFRA T, Waissengrin B, Gerber D, Bernstein-Molho R, et al
    Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
    Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00489.
    >> Share

  169. WAGAR MK, Sobecki JN, Chandereng T, Hartenbach EM, et al
    Postoperative venous thromboembolism in gynecologic oncology patients undergoing minimally invasive surgery: Does modality matter?
    Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00491.
    >> Share

  170. BALDEWPERSAD TEWARIE NMS, van Driel WJ, van Ham M, Wouters MW, et al
    Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00436.
    >> Share

  171. JIANG C, Li Z
    Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00483.
    >> Share

  172. FAN Y, Zhang YF, Wang MY, Mu Y, et al
    Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00439.
    >> Share

  173. HICKEY M, Moss KM, Krejany EO, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12months after premenopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2021 Jun 8. pii: S0090-8258(21)00442.
    >> Share

  174. VAN DER ZANDEN V, van Soolingen NJ, Viddeleer AR, Trum JW, et al
    Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00445.
    >> Share

  175. AGHAJANIAN C, Bookman MA, Fleming GF, Swisher EM, et al
    Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00437.
    >> Share

  176. CASPER AC, Parsons MW, Chipman J, Burt LM Jr, et al
    Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00440.
    >> Share

  177. LI S, Bercow AS, Falzone M, Kalyanaraman R, et al
    Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00438.
    >> Share

  178. HANLEY GE, Kaur P, Berchuck A, Chase A, et al
    Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00427.
    >> Share

  179. ALVAREZ SECORD A, O'Malley DM, Sood AK, Westin SN, et al
    Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Gynecol Oncol. 2021 Jun 2. pii: S0090-8258(21)00424.
    >> Share

  180. SHARMA A, Singh M, Chauhan R, Malik PS, et al
    Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00431.
    >> Share

  181. SUE-A-QUAN R, Patel PG, Shakfa N, Nyi MN, et al
    Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00406.
    >> Share

    May 2021
  182. FRANGOU E, Bertelli G, Love S, Mackean MJ, et al
    OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.
    Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00430.
    >> Share

  183. HAVRILESKY LJ, Scott AL, Davidson BA, Secord AA, et al
    The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00428.
    >> Share

  184. DE JONG JM, Hoogendam JP, Braat AJAT, Zweemer RP, et al
    The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00423.
    >> Share

  185. MANNING-GEIST BL, Chi DS, Long Roche K, Zivanovic O, et al
    Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
    Gynecol Oncol. 2021 May 25. pii: S0090-8258(21)00421.
    >> Share

  186. LIN J, Sharaf RN, Saganty R, Ahsan D, et al
    Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
    Gynecol Oncol. 2021 May 19. pii: S0090-8258(21)00407.
    >> Share

  187. HEMMINGSEN CH, Kjaer SK, Bennetsen AKK, Dehlendorff C, et al
    The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
    Gynecol Oncol. 2021 May 17. pii: S0090-8258(21)00404.
    >> Share

  188. KIM SI, Yoon S, Kim TM, Cho JY, et al
    Prognostic implications of body composition change during primary treatment in patients with ovarian cancer: A retrospective study using an artificial intelligence-based volumetric technique.
    Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00363.
    >> Share

  189. TRAN DT, Vo VK, Le MT, Chuang L, et al
    Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study.
    Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00360.
    >> Share

  190. CABRERA S, Barahona-Orpinell M, Almansa-Gonzalez C, Padilla-Iserte P, et al
    Combined use of ICG and technetium does not improve sentinel lymph node detection in endometrial cancer: Results of the COMBITEC study.
    Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00361.
    >> Share

  191. HICKEY M, Moss KM, Mishra GD, Krejany EO, et al
    What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Gynecol Oncol. 2021 May 7. pii: S0090-8258(21)00358.
    >> Share

  192. CAO L, Wei M, Liu Y, Fu J, et al
    Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses.
    Gynecol Oncol. 2021 May 6. pii: S0090-8258(21)00351.
    >> Share

  193. CHAM S, Huang Y, Melamed A, Worley MJ Jr, et al
    Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival.
    Gynecol Oncol. 2021 May 5. pii: S0090-8258(21)00352.
    >> Share

  194. GAMBLE CR, Huang Y, Wright JD, Hou JY, et al
    Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs medicaid insurance.
    Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00345.
    >> Share

  195. SIMS TT, Boruta DM
    Sentinel lymph node isolated tumor cells in early staged endometrioid endometrial cancer: Utility or futility?
    Gynecol Oncol. 2021;161:331-332.
    >> Share

  196. GILLEN J, Miller A, Bell-McGuinn KM, Schilder RJ, et al
    Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
    Gynecol Oncol. 2021;161:512-515.
    >> Share

    April 2021
  197. MULLINS MA, Ruterbusch JJ, Clarke P, Uppal S, et al
    Continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer.
    Gynecol Oncol. 2021 Apr 27. pii: S0090-8258(21)00344.
    >> Share

  198. GIANNONE G, Scotto G, Katsaros D, De Giorgi U, et al
    Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
    Gynecol Oncol. 2021 Apr 22. pii: S0090-8258(21)00328.
    >> Share

  199. THUSGAARD CF, Korsholm M, Koldby KM, Kruse TA, et al
    Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review.
    Gynecol Oncol. 2021 Apr 20. pii: S0090-8258(21)00330.
    >> Share

  200. SWAYZE EJ, Strzyzewski L, Avula P, Zebolsky AL, et al
    The impact of expanding gynecologic oncology care to ovarian cancer patients in small cities and rural communities.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00331.
    >> Share

  201. MARTINEZ A, Buckley M, Scalise CB, Katre AA, et al
    Understanding the effect of mechanical forces on ovarian cancer progression.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00273.
    >> Share

  202. ARTIOLI G, Giannone G, Valabrega G, Maggiorotto F, et al
    Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00324.
    >> Share

  203. DENG M, Wu D, Zhang Y, Jin Z, et al
    MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
    Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00323.
    >> Share

  204. SHIM SH, Chae SH, So KA, Lee SJ, et al
    Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer.
    Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00270.
    >> Share

  205. NITECKI R, Fleming ND, Fellman BM, Meyer LA, et al
    Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00322.
    >> Share

  206. GUPTA VG, Hirst J, Petersen S, Roby KF, et al
    Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00325.
    >> Share

  207. TONE AA, McCuaig JM, Ricker N, Boghosian T, et al
    The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    Gynecol Oncol. 2021 Apr 13. pii: S0090-8258(21)00321.
    >> Share

  208. VAN DE VORST REWM, Hoogendam JP, van der Aa MA, Witteveen PO, et al
    The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Apr 10. pii: S0090-8258(21)00317.
    >> Share

  209. FLEMING ND, Westin SN, Rauh-Hain JA, Soliman PT, et al
    Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Apr 7. pii: S0090-8258(21)00272.
    >> Share

  210. CHASE DM, Neighbors J, Perhanidis J, Monk BJ, et al
    Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay.
    Gynecol Oncol. 2021 Apr 1. pii: S0090-8258(21)00259.
    >> Share

  211. CRAMER DW, Vitonis AF, Sasamoto N, Yamamoto H, et al
    Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES).
    Gynecol Oncol. 2021;161:282-290.
    >> Share

  212. JOU J, Zimmer Z, Charo L, Yau C, et al
    HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
    Gynecol Oncol. 2021;161:25-33.
    >> Share

    March 2021
  213. MALLEN A, Todd S, Robertson SE, Kim J, et al
    Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00228.
    >> Share

  214. RAFFONE A, Catena U, Travaglino A, Masciullo V, et al
    Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00267.
    >> Share

  215. GEOFFRON S, Lier A, de Kermadec E, Sermondade N, et al
    Fertility preservation in women with malignant and borderline ovarian tumors: Experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG).
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00268.
    >> Share

  216. GIL-MORENO A, Alonso-Alconada L, Diaz-Feijoo B, Domingo S, et al
    M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients.
    Gynecol Oncol. 2021 Mar 29. pii: S0090-8258(21)00260.
    >> Share

  217. FALCONE F, Breda E, Ferrandina G, Malzoni M, et al
    Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database.
    Gynecol Oncol. 2021 Mar 26. pii: S0090-8258(21)00261.
    >> Share

  218. CARTMEL B, Hughes M, Ercolano EA, Gottlieb L, et al
    Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC).
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00195.
    >> Share

  219. FILIPPOVA OT, Tin AL, Alonso J, Vickers AJ, et al
    Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00252.
    >> Share

  220. ZHANG X, Devins K, Ko EM, Reyes MC, et al
    Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00257.
    >> Share

  221. NASIOUDIS D, Byrne M, Ko EM, Giuntoli RL 2nd, et al
    Outcomes of sentinel lymph node mapping for patients with FIGO stage I endometrioid endometrial carcinoma.
    Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00256.
    >> Share

  222. KONECNY GE, Oza AM, Tinker AV, Oaknin A, et al
    Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
    Gynecol Oncol. 2021 Mar 19. pii: S0090-8258(21)00235.
    >> Share

  223. LOREEN A, Polen-De C, Monk BJ, Jackson AL, et al
    The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00176.
    >> Share

  224. HASSELGREN E, Hertzberg D, Camderman T, Bjorne H, et al
    Perioperative fluid balance and major postoperative complications in surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00179.
    >> Share

  225. ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Mar 11. pii: S0090-8258(21)00229.
    >> Share

  226. MORDEN CR, Farrell AC, Sliwowski M, Lichtensztejn Z, et al
    Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Gynecol Oncol. 2021 Mar 10. pii: S0090-8258(21)00199.
    >> Share

  227. LAGO V, Montero B, Lopez S, Padilla-Iserte P, et al
    Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00193.
    >> Share

  228. BUECHEL ME, Enserro D, Burger RA, Brady MF, et al
    Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00177.
    >> Share

  229. COWAN R, Nobre SP, Pradhan N, Yasukawa M, et al
    Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00142.
    >> Share

  230. BACKES FJ, Felix AS, Plante M, Gregoire J, et al
    Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
    Gynecol Oncol. 2021 Mar 4. pii: S0090-8258(21)00154.
    >> Share

  231. HUANG C, Lin X, He J, Liu N, et al
    Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00169.
    >> Share

  232. FILIPPOVA OT, Selenica P, Pareja F, Vahdatinia M, et al
    Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00173.
    >> Share

  233. AUBREY C, Saad N, Kobel M, Mattatall F, et al
    Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status.
    Gynecol Oncol. 2021 Mar 1. pii: S0090-8258(21)00158.
    >> Share

    February 2021
  234. SCHRIER E, Xiong N, Thompson E, Poort H, et al
    Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00168.
    >> Share

  235. SJOQUIST KM, Espinoza D, Mileshkin L, Ananda S, et al
    REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00109.
    >> Share

  236. AREND RC, Monk BJ, Herzog TJ, Moore KN, et al
    Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum r
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00151.
    >> Share

  237. DA CRUZ PAULA A, DeLair DF, Ferrando L, Fix DJ, et al
    Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
    Gynecol Oncol. 2021 Feb 20. pii: S0090-8258(21)00152.
    >> Share

  238. KURTZ JE, Gebski V, Sukhin V, Carey M, et al
    Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
    Gynecol Oncol. 2021 Feb 18. pii: S0090-8258(21)00155.
    >> Share

  239. INCI MG, Anders L, Woopen H, Richter R, et al
    Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study.
    Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00149.
    >> Share

  240. BAANDRUP L, Dehlendorff C, Hertzum-Larsen R, Hannibal CG, et al
    Prognostic impact of socioeconomic status on long-term survival of non-localized epithelial ovarian cancer The Extreme study.
    Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00102.
    >> Share

  241. HICKEY M, Moss KM, Brand A, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00108.
    >> Share

  242. DAHM-KAHLER P, Holmberg E, Holtenman M, Radestad AF, et al
    Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
    Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00059.
    >> Share

  243. CHAMBERS LM, Yao M, Morton M, Gruner M, et al
    Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00099.
    >> Share

  244. RAHIMY E, Usoz M, von Eyben R, Fujimoto D, et al
    Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00093.
    >> Share

  245. LIU S, Kasherman L, Fazelzad R, Wang L, et al
    The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Feb 2. pii: S0090-8258(21)00088.
    >> Share

    January 2021
  246. HARRISON RF, Cantor SB, Sun CC, Villanueva M, et al
    Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
    Gynecol Oncol. 2021 Jan 31. pii: S0090-8258(21)00084.
    >> Share

  247. PIZZOFERRATO AC, Klein M, Fauvet R, Durand C, et al
    Pelvic floor disorders and sexuality in women with ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 Jan 27. pii: S0090-8258(21)00086.
    >> Share

  248. TOZZI R, Traill Z, Valenti G, Ferrari F, et al
    A prospective study on the diagnostic pathway of patients with stage IIIC-IV ovarian cancer: Exploratory laparoscopy (EXL) + CT scan VS. CT scan.
    Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00060.
    >> Share

  249. KIM SR, Tone A, Kim RH, Cesari M, et al
    Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
    Gynecol Oncol. 2021 Jan 18. pii: S0090-8258(21)00002.
    >> Share

  250. NOVIKOVA OV, Nosov VB, Panov VA, Novikova EG, et al
    Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Gynecol Oncol. 2021 Jan 15. pii: S0090-8258(21)00001.
    >> Share

  251. CASTLE PE, Locke A, Tergas AI, Befano B, et al
    The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(21)00052.
    >> Share

  252. SCHEEPERS ERM, de Rooij BH, Pijnenborg JMA, van Huis-Tanja LH, et al
    Perceived social support in patients with endometrial or ovarian cancer: A secondary analysis from the ROGY care study.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(20)34246.
    >> Share

  253. BILBAO M, Aikins JK, Ostrovsky O
    Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications.
    Gynecol Oncol. 2021 Jan 9. pii: S0090-8258(20)34248.
    >> Share

  254. HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
    The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
    Gynecol Oncol. 2021 Jan 7. pii: S0090-8258(20)34255.
    >> Share

  255. DELLINGER TH, Han ES
    State of the Science: The role of HIPEC in the treatment of ovarian cancer.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34243.
    >> Share

  256. HEUS C, Smorenburg A, Stoker J, Rutten MJ, et al
    Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study.
    Gynecol Oncol. 2021;160:187-192.
    >> Share

  257. FADADU PP, Polen-De CL, McGree ME, Weaver AL, et al
    Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
    Gynecol Oncol. 2021;160:40-44.
    >> Share

    December 2020
  258. DUSKA LR, Krasner CN, O'Malley DM, Hays JL, et al
    A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Gynecol Oncol. 2020 Dec 31. pii: S0090-8258(20)34228.
    >> Share

  259. BOERNER T, Walch HS, Nguyen B, Iasonos A, et al
    Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.
    Gynecol Oncol. 2020 Dec 29. pii: S0090-8258(20)34225.
    >> Share

  260. LIANG MI, Chen L, Hershman DL, Hillyer GC, et al
    Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
    Gynecol Oncol. 2020 Dec 27. pii: S0090-8258(20)34218.
    >> Share

  261. GHEZELAYAGH TS, Pennington KP, Norquist BM, Khasnavis N, et al
    Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34178.
    >> Share

  262. PHILP L, Tannenbaum S, Haber H, Saini A, et al
    Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
    Gynecol Oncol. 2020 Dec 23. pii: S0090-8258(20)34174.
    >> Share

  263. GUO Y, Jiang T, Ouyang L, Li X, et al
    A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses.
    Gynecol Oncol. 2020 Dec 20. pii: S0090-8258(20)34177.
    >> Share

  264. BANVILLE AC, Wouters MCA, Oberg AL, Goergen KM, et al
    Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Gynecol Oncol. 2020 Dec 17. pii: S0090-8258(20)34176.
    >> Share

  265. KARNEZIS AN, Chen SY, Chow C, Yang W, et al
    Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
    Gynecol Oncol. 2020 Dec 13. pii: S0090-8258(20)34175.
    >> Share

  266. YUE H, Li W, Chen R, Wang J, et al
    Stromal POSTN induced by TGF-beta1 facilitates the migration and invasion of ovarian cancer.
    Gynecol Oncol. 2020 Dec 11. pii: S0090-8258(20)34154.
    >> Share

  267. GOTOH O, Kiyotani K, Chiba T, Sugiyama Y, et al
    Immunogenomic landscape of gynecologic carcinosarcoma.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34158.
    >> Share

  268. STOVER EH, Fuh K, Konstantinopoulos PA, Matulonis UA, et al
    Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Gynecol Oncol. 2020;159:887-898.
    >> Share

  269. WANG Z, Yin P, Sun Y, Na L, et al
    LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
    Gynecol Oncol. 2020;159:839-849.
    >> Share

  270. FUH K, Mullen M, Blachut B, Stover E, et al
    Homologous recombination deficiency real-time clinical assays, ready or not?
    Gynecol Oncol. 2020;159:877-886.
    >> Share

  271. VETTER MH, Castaneda A, Khan A, O'Malley DM, et al
    A clinical classification system for grading platinum hypersensitivity reactions.
    Gynecol Oncol. 2020;159:794-798.
    >> Share

    November 2020
  272. STRAUBHAR AM, Wolf JL, Zhou MQC, Iasonos A, et al
    Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
    Gynecol Oncol. 2020 Nov 30. pii: S0090-8258(20)34132.
    >> Share

  273. HULSTAERT E, Morlion A, Levanon K, Vandesompele J, et al
    Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review.
    Gynecol Oncol. 2020 Nov 27. pii: S0090-8258(20)34129.
    >> Share

  274. WU L, Zhu J, Yin R, Wu X, et al
    Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
    Gynecol Oncol. 2020 Nov 26. pii: S0090-8258(20)34013.
    >> Share

  275. CONSIDINE DPC, Jia G, Shu X, Schildkraut JM, et al
    Genetically predicted circulating protein biomarkers and ovarian cancer risk.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34127.
    >> Share

  276. CHO A, Lee SW, Park JY, Kim DY, et al
    Continued medical treatment for persistent early endometrial cancer in young women.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34115.
    >> Share

  277. CHELARIU-RAICU A, Nick A, Urban R, Gordinier M, et al
    A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
    Gynecol Oncol. 2020 Nov 23. pii: S0090-8258(20)34124.
    >> Share

  278. KHATIB G, Seyfettinoglu S, Guzel AB, Gulec UK, et al
    Feasibility and rationale of a novel approach in advanced ovarian cancer surgery: Bat- shaped en-bloc total peritonectomy and total hysterectomy salpingo-oophorectomy with or without rectosigmoid resection (Sarta-Bat approach).
    Gynecol Oncol. 2020 Nov 21. pii: S0090-8258(20)34122.
    >> Share

  279. FEJZO MS, Chen HW, Anderson L, McDermott MS, et al
    Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34116.
    >> Share

  280. MORSE CB, Voillet V, Bates BM, Chiu EY, et al
    Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34117.
    >> Share

  281. RANA HQ, Kipnis L, Hehir K, Cronin A, et al
    Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34111.
    >> Share

  282. FREY MK, Chapman-Davis E, Glynn SM, Lin J, et al
    Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic.
    Gynecol Oncol. 2020 Nov 19. pii: S0090-8258(20)34128.
    >> Share

  283. XU Y, Jia Y, Zhang Q, Du Y, et al
    Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34121.
    >> Share

  284. WEEKS K, Lynch CF, West M, Carnahan R, et al
    Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients.
    Gynecol Oncol. 2020 Nov 17. pii: S0090-8258(20)34114.
    >> Share

  285. BOERNER T, Tanner E, Filippova O, Zhou QC, et al
    Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34064.
    >> Share

  286. O'TOOLE SA, Huang Y, Norris L, Power Foley M, et al
    HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34112.
    >> Share

  287. CHEN F, Bailey CE, Alvarez RD, Shu XO, et al
    Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer.
    Gynecol Oncol. 2020 Nov 15. pii: S0090-8258(20)34062.
    >> Share

  288. POORT H, Fenton ATHR, Thompson E, Dinardo MM, et al
    Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34056.
    >> Share

  289. KIMBLE DC, Dvergsten E, Thomeas-McEwing V, Karovic S, et al
    Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34066.
    >> Share

  290. WALL JA, Meza-Perez S, Scalise CB, Katre A, et al
    Manipulating the Wnt/beta-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34053.
    >> Share

  291. WESLEY E, Uppendahl LD, Felices M, Dahl C, et al
    Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34051.
    >> Share

  292. BIZZARRI N, du Bois A, Fruscio R, De Felice F, et al
    Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34050.
    >> Share

  293. BLANC-DURAND F, Genestie C, Galende EY, Gouy S, et al
    Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
    Gynecol Oncol. 2020 Nov 5. pii: S0090-8258(20)33955.
    >> Share

  294. RUSSELL B, Hawarden A, Gee M, Edmondson RJ, et al
    Propensity score matching confirms that primary surgery or neoadjuvant chemotherapy result in equivalent survival within a comprehensive cohort of patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34057.
    >> Share

  295. DIAZ-FEIJOO B, Bebia V, Hernandez A, Gilabert-Estalles J, et al
    Surgical complications comparing extraperitoneal vs transperitoneal laparoscopic aortic staging in early stage ovarian and endometrial cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34060.
    >> Share

    October 2020
  296. RUBINSTEIN MM, Grisham RN, Cadoo K, Kyi C, et al
    A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
    Gynecol Oncol. 2020 Oct 30. pii: S0090-8258(20)34041.
    >> Share

  297. ELAYAPILLAI S, Ramraj S, Benbrook DM, Bieniasz M, et al
    Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
    Gynecol Oncol. 2020 Oct 29. pii: S0090-8258(20)34018.
    >> Share

  298. MATSUO K, Matsuzaki S, Nusbaum DJ, Maoz A, et al
    Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
    Gynecol Oncol. 2020 Oct 23. pii: S0090-8258(20)34049.
    >> Share

  299. CEPPI L, Grassi T, Galli F, Buda A, et al
    Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34036.
    >> Share

  300. HALL MR, Dehbi HM, Banerjee S, Lord R, et al
    A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)33958.
    >> Share

  301. BARBER EL, Garg R, Persenaire C, Simon M, et al
    Natural language processing with machine learning to predict outcomes after ovarian cancer surgery.
    Gynecol Oncol. 2020 Oct 14. pii: S0090-8258(20)34012.
    >> Share

  302. MORTON M, Chambers LM, Costales AB, Chichura A, et al
    Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 13. pii: S0090-8258(20)33962.
    >> Share

  303. MICHELS J, Genestie C, Dunant A, Caron O, et al
    Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
    Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33960.
    >> Share

  304. HAUNSCHILD CE, Tewari KS
    The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 11. pii: S0090-8258(20)33953.
    >> Share

  305. CARR C, Son J, Yao M, Priyadarshini A, et al
    Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
    Gynecol Oncol. 2020 Oct 9. pii: S0090-8258(20)33949.
    >> Share

  306. NICA A, Lee JYJ, Hong NL, May T, et al
    Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 6. pii: S0090-8258(20)33961.
    >> Share

  307. CORVIGNO S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, et al
    High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33951.
    >> Share

  308. CICCONE MA, Adams CL, Bowen C, Thakur T, et al
    Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33950.
    >> Share

  309. UBACHS J, Koole SN, Lahaye M, Fabris C, et al
    No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33952.
    >> Share

  310. GERSHENSON DM, Cobb LP, Sun CC
    Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33959.
    >> Share

  311. LENTZ SE, Powell CB, Haque R, Armstrong MA, et al
    Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
    Gynecol Oncol. 2020 Oct 1. pii: S0090-8258(20)33914.
    >> Share

  312. EAKIN CM, Ewongwo A, Pendleton L, Monk BJ, et al
    Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Gynecol Oncol. 2020;159:112-117.
    >> Share

  313. SALANI R, Liu JF
    Meeting report from the 2020 Annual (virtual) Meeting of the American Society of Clinical Oncology.
    Gynecol Oncol. 2020;159:13-16.
    >> Share

  314. CRESTANI A, Benoit L, Touboul C, Pasquier J, et al
    Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment?
    Gynecol Oncol. 2020;159:285-294.
    >> Share

    September 2020
  315. KOTSOPOULOS J, Gronwald J, McCuaig JM, Karlan BY, et al
    Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33947.
    >> Share

  316. CHAN JK, Liang SY, Kapp DS, Chan JE, et al
    Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33910.
    >> Share

  317. LANDOLFO C, Achten ETL, Ceusters J, Baert T, et al
    Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33918.
    >> Share

  318. MIRZA MR, Benigno B, Dorum A, Mahner S, et al
    Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33899.
    >> Share

  319. WICHMANN C, Klotz DM, Zeiler HJ, Hilger RA, et al
    The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33911.
    >> Share

  320. MANRRIQUEZ E, Mandelbaum A, Aguayo E, Zakhour M, et al
    Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33919.
    >> Share

  321. CHARO LM, Jou J, Binder P, Hohmann SF, et al
    Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33915.
    >> Share

  322. JOHNSON KE, Popratiloff A, Fan Y, McDonald S, et al
    Analytic comparison of talc in commercially available baby powder and in pelvic tissues resected from ovarian carcinoma patients.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33921.
    >> Share

  323. EAKIN CM, Norton TJ, Monk BJ, Chase DM, et al
    Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33817.
    >> Share

  324. MUSORO JZ, Coens C, Greimel E, King MT, et al
    Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33900.
    >> Share

  325. BANTIE L, Tadesse S, Likisa J, Yu M, et al
    A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33905.
    >> Share

  326. GUNAY G, Kirit HA, Kamatar A, Baghdasaryan O, et al
    The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33857.
    >> Share

  327. MUSTON D, Hettle R, Monberg M, McLaurin KK, et al
    Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33814.
    >> Share

  328. KANBERGS AN, Manning-Geist BL, Pelletier A, Sullivan MW, et al
    Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33904.
    >> Share

  329. JORDAN SE, Saad H, Covarrubias AS, Siemon J, et al
    mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population.
    Gynecol Oncol. 2020 Sep 17. pii: S0090-8258(20)33831.
    >> Share

  330. CHAMBERS LM, Kuznicki M, Yao M, Chichura A, et al
    Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Sep 16. pii: S0090-8258(20)33903.
    >> Share

  331. PALMQVIST C, Staf C, Mateoiu C, Johansson M, et al
    Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment.
    Gynecol Oncol. 2020 Sep 15. pii: S0090-8258(20)33897.
    >> Share

  332. HURWITZ LM, Pinsky PF, Huang WY, Freedman ND, et al
    Aspirin use and ovarian cancer risk using extended follow-up of the PLCO Cancer Screening Trial.
    Gynecol Oncol. 2020 Sep 10. pii: S0090-8258(20)33855.
    >> Share

  333. PLETT H, Filippova OT, Garbi A, Kommoss S, et al
    Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study.
    Gynecol Oncol. 2020 Sep 9. pii: S0090-8258(20)33829.
    >> Share

  334. MADARIAGA A, Garg S, Bruce JP, Thiryayi S, et al
    Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer.
    Gynecol Oncol. 2020 Sep 7. pii: S0090-8258(20)33849.
    >> Share

  335. WALLBILLICH JJ, Morris RT, Ali-Fehmi R
    Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
    Gynecol Oncol. 2020 Sep 5. pii: S0090-8258(20)33813.
    >> Share

  336. DI DONATO V, Di Pinto A, Giannini A, Caruso G, et al
    Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 4. pii: S0090-8258(20)33823.
    >> Share

    August 2020
  337. SIA TY, Wen T, Cham S, Friedman AM, et al
    Effect of frailty on postoperative readmissions and cost of care for ovarian cancer.
    Gynecol Oncol. 2020 Aug 28. pii: S0090-8258(20)33825.
    >> Share

  338. GONZALEZ R, Havrilesky LJ, Myers ER, Secord AA, et al
    Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
    Gynecol Oncol. 2020 Aug 27. pii: S0090-8258(20)33759.
    >> Share

  339. SHEN L, Xie L, Li R, Shan B, et al
    A preoperative prediction model for predicting coexisting adnexa malignancy of patients with G1/G2 endometrioid endometrial cancer.
    Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33818.
    >> Share

  340. BELL SG, Dalton L, McNeish BL, Fang F, et al
    Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients.
    Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33816.
    >> Share

  341. RICHARDSON MT, Mysona DP, Klein DA, Mann A, et al
    Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit.
    Gynecol Oncol. 2020 Aug 20. pii: S0090-8258(20)32386.
    >> Share

  342. AVIKI EM, Lavery JA, Roche KL, Cowan R, et al
    Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.
    Gynecol Oncol. 2020 Aug 16. pii: S0090-8258(20)33754.
    >> Share

  343. BOERNER T, Filippova OT, Chi AJ, Iasonos A, et al
    Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
    Gynecol Oncol. 2020 Aug 10. pii: S0090-8258(20)33751.
    >> Share

  344. POTHURI B, O'Cearbhaill R, Eskander R, Armstrong D, et al
    Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
    Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33747.
    >> Share

  345. POWELL CB, Laurent C, Ciaravino G, Garcia C, et al
    Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
    Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33662.
    >> Share

  346. BEESLEY VL, Webber K, Nagle CM, DeFazio A, et al
    When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer.
    Gynecol Oncol. 2020 Aug 6. pii: S0090-8258(20)33664.
    >> Share

  347. LEE EK, Xiong N, Cheng SC, Barry WT, et al
    Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
    Gynecol Oncol. 2020 Aug 5. pii: S0090-8258(20)33663.
    >> Share

    July 2020
  348. LEE JM, Annunziata CM, Hays JL, Cao L, et al
    Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
    Gynecol Oncol. 2020 Jul 31. pii: S0090-8258(20)33677.
    >> Share

  349. COLOMBO N, Oza AM, Lorusso D, Aghajanian C, et al
    The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
    Gynecol Oncol. 2020 Jul 31. pii: S0090-8258(20)31130.
    >> Share

  350. TEWARI KS, Sill MW, Coleman RL, Aghajanian C, et al
    Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)32390.
    >> Share

  351. SCHWARTZ GG, Tretli S, Klug MG, Robsahm TE, et al
    Women who develop ovarian cancer show an increase in serum calcium and a decrease in serum albumin. A longitudinal study in the Janus Serum Bank Cohort.
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)32381.
    >> Share

  352. BLANC-DURAND F, Lefeuvre-Plesse C, Ray-Coquard I, Chaltiel D, et al
    Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)33654.
    >> Share

  353. ROBELIN P, Tod M, Colomban O, Lachuer J, et al
    Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)33656.
    >> Share

  354. FALCONER H, Joneborg U, Krawiec K, Palsdottir K, et al
    Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32384.
    >> Share

  355. ANGELES MA, Rychlik A, Cabarrou B, Spagnolo E, et al
    A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32321.
    >> Share

  356. COBB LP, Sun CC, Iyer R, Nick AM, et al
    The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32324.
    >> Share

  357. WEISS AS, Swisher E, Pennington KP, Radke M, et al
    Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
    Gynecol Oncol. 2020 Jul 21. pii: S0090-8258(20)32335.
    >> Share

  358. LORUSSO D, Marchetti C, Conte C, Giudice E, et al
    Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study.
    Gynecol Oncol. 2020 Jul 20. pii: S0090-8258(20)33657.
    >> Share

  359. TAYLAN E, Zayou F, Murali R, Karlan BY, et al
    Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model.
    Gynecol Oncol. 2020 Jul 19. pii: S0090-8258(20)32380.
    >> Share

  360. WU JL, Zhao J, Zhang HB, Zuo WW, et al
    Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32387.
    >> Share

  361. ZHENG L, Cui C, Shi O, Lu X, et al
    Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990-2017.
    Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32383.
    >> Share

  362. MCCUAIG JM, Care M, Ferguson SE, Kim RH, et al
    Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
    Gynecol Oncol. 2020 Jul 13. pii: S0090-8258(20)32333.
    >> Share

  363. ROSS TL, DeFazio A, Friedlander M, Grant P, et al
    Insomnia and its association with quality of life in women with ovarian cancer.
    Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)32326.
    >> Share

  364. PRESSEY JG, Dandoy CE, Pater LE, Sroga Rios J, et al
    Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult.
    Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)31975.
    >> Share

  365. BERNARD L, Boucher J, Helpman L
    Bowel resection or repair at the time of cytoreductive surgery for ovarian malignancy is associated with increased complication rate: An ACS-NSQIP study.
    Gynecol Oncol. 2020 Jul 6. pii: S0090-8258(20)32330.
    >> Share

  366. BRIEGER KK, Peterson S, Lee AW, Mukherjee B, et al
    Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.
    Gynecol Oncol. 2020 Jul 5. pii: S0090-8258(20)32296.
    >> Share

  367. DERQUIN F, Floquet A, Hardy-Bessard AC, Edeline J, et al
    Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
    Gynecol Oncol. 2020 Jul 2. pii: S0090-8258(20)32315.
    >> Share

  368. BAE-JUMP V
    Unraveling the mystery of clear cell endometrial cancer.
    Gynecol Oncol. 2020;158:1-2.
    >> Share

    June 2020
  369. JONES TL, Sandler CX, Spence RR, Hayes SC, et al
    Physical activity and exercise in women with ovarian cancer: A systematic review.
    Gynecol Oncol. 2020 Jun 29. pii: S0090-8258(20)32300.
    >> Share

  370. LAGO V, Fotopoulou C, Chiantera V, Minig L, et al
    Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)31132.
    >> Share

  371. SIMPSON AN, Sutradhar R, Ferguson SE, Robertson D, et al
    Perioperative outcomes of women with and without class III obesity undergoing hysterectomy for endometrioid endometrial cancer: A population-based study.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32295.
    >> Share

  372. MARIA S, Faron M, Maulard A, Pautier P, et al
    Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32304.
    >> Share

  373. DILLEY J, Burnell M, Gentry-Maharaj A, Ryan A, et al
    Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)31029.
    >> Share

  374. NICA A, Covens A, Parra-Herran C, May T, et al
    Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
    Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)32293.
    >> Share

  375. PYRZAK A, Chen L, Kocherginsky M, Barber EL, et al
    Radiation and hormonal therapy for primary treatment of stage I endometrial cancer and long-term survival.
    Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)31088.
    >> Share

  376. MARCHETTI C, Minucci A, D'Indinosante M, Ergasti R, et al
    Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
    Gynecol Oncol. 2020 Jun 15. pii: S0090-8258(20)32294.
    >> Share

  377. MOORE KN, Birrer MJ, Marsters J, Wang Y, et al
    Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2020 Jun 11. pii: S0090-8258(20)31124.
    >> Share

  378. NARASIMHULU DM, McGree ME, Weaver AL, Jatoi A, et al
    Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31131.
    >> Share

  379. BOGANI G, Lopez S, Mantiero M, Ducceschi M, et al
    Immunotherapy for platinum-resistant ovarian cancer.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31924.
    >> Share

  380. STRAUBHAR AM, Filippova OT, Cowan RA, Lakhman Y, et al
    A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31126.
    >> Share

  381. HAMILTON E, O'Malley DM, O'Cearbhaill R, Cristea M, et al
    Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
    Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31123.
    >> Share

  382. MORRISON A, Nasioudis D
    Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature.
    Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31121.
    >> Share

  383. VENERIS JT, Mahajan P, Frazier AL
    Contemporary management of ovarian germ cell tumors and remaining controversies.
    Gynecol Oncol. 2020 Jun 4. pii: S0090-8258(20)31075.
    >> Share

  384. ARMEL SR, Volenik A, Demsky R, Malcolmson J, et al
    Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.
    Gynecol Oncol. 2020 Jun 3. pii: S0090-8258(20)31082.
    >> Share

  385. BOLAND JL, Zhou Q, Iasonos AE, O'Cearbhaill RE, et al
    Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy.
    Gynecol Oncol. 2020 Jun 2. pii: S0090-8258(20)31073.
    >> Share

  386. ROCHE KL, Chi DS
    Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward...or too much risk?
    Gynecol Oncol. 2020;157:561-562.
    >> Share

  387. CHAMBERS LM, Pendlebury A, Rose PG, Yao M, et al
    Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2020 Jun 1. pii: S0090-8258(20)31018.
    >> Share

  388. CHEN H, Gotimer K, De Souza C, Tepper CG, et al
    Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
    Gynecol Oncol. 2020;157:783-792.
    >> Share

  389. DUSKA LR, Petroni GR, Varhegyi N, Brown J, et al
    A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
    Gynecol Oncol. 2020;157:585-592.
    >> Share

    May 2020
  390. KNISELY A, Huang Y, Melamed A, Tergas AI, et al
    Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes.
    Gynecol Oncol. 2020 May 23. pii: S0090-8258(20)31085.
    >> Share

  391. GLEESON M, Kentwell M, Meiser B, Do J, et al
    The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.
    Gynecol Oncol. 2020 May 22. pii: S0090-8258(20)31028.
    >> Share

  392. SMAZYNSKI J, Hamilton PT, Thornton S, Milne K, et al
    The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Gynecol Oncol. 2020 May 20. pii: S0090-8258(20)30989.
    >> Share

  393. MATSUO K, Chang EJ, Matsuzaki S, Mandelbaum RS, et al
    Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes.
    Gynecol Oncol. 2020 May 10. pii: S0090-8258(20)30304.
    >> Share

  394. LUO S, Zhang Y, Yang Y, Zhu S, et al
    Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.
    Gynecol Oncol. 2020 May 8. pii: S0090-8258(20)30995.
    >> Share

  395. BOUCHARD-FORTIER G, Cusimano MC, Fazelzad R, Sajewycz K, et al
    Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 May 6. pii: S0090-8258(20)30259.
    >> Share

  396. SIVAKUMARAN T, Mileshkin L, Grant P, Na L, et al
    Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)31016.
    >> Share

  397. DAI Y, Wang Z, Wang J
    Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data.
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)30984.
    >> Share

  398. SONG F, Li L, Zhang B, Zhao Y, et al
    Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Gynecol Oncol. 2020 May 1. pii: S0090-8258(20)30988.
    >> Share

    April 2020
  399. STAPLES JN, Peres LC, Camacho F, Alberg AJ, et al
    Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).
    Gynecol Oncol. 2020 Apr 30. pii: S0090-8258(20)31010.
    >> Share

  400. MONK BJ, Coleman RL, Moore KN, Herzog TJ, et al
    COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies.
    Gynecol Oncol. 2020 Apr 29. pii: S0090-8258(20)31013.
    >> Share

  401. CHEN Y, Li G
    Gynecological malignancies with asymptomatic SARS-CoV-2 infection during the convalescence of outbreak.
    Gynecol Oncol. 2020 Apr 29. pii: S0090-8258(20)31019.
    >> Share

  402. NASIOUDIS D, Ko EM, Haggerty AF, Cory L, et al
    Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy.
    Gynecol Oncol. 2020 Apr 28. pii: S0090-8258(20)30306.
    >> Share

  403. SEARLE G, Pounds R, Phillips A, Kehoe S, et al
    Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis.
    Gynecol Oncol. 2020 Apr 25. pii: S0090-8258(20)30307.
    >> Share

  404. MAJIDI A, Na R, Dixon-Suen S, Jordan SJ, et al
    Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Apr 18. pii: S0090-8258(20)30253.
    >> Share

  405. HOOGSTAD-VAN EVERT JS, Bekkers R, Ottevanger N, Jansen JH, et al
    Harnessing natural killer cells for the treatment of ovarian cancer.
    Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30236.
    >> Share

  406. AREND RC, Beer HM, Cohen YC, Berlin S, et al
    Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
    Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30180.
    >> Share

  407. NARASIMHULU DM, Kumar A, Weaver AL, Langstraat CL, et al
    Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management.
    Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30249.
    >> Share

  408. CHEVROT A, Pouget N, Bats AS, Huchon C, et al
    Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group.
    Gynecol Oncol. 2020;157:29-35.
    >> Share

  409. SCOTT SA, Llaurado Fernandez M, Kim H, Elit L, et al
    Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
    Gynecol Oncol. 2020;157:36-45.
    >> Share

  410. MUELLER JJ, Pedra Nobre S, Braxton K, Alektiar KM, et al
    Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.
    Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30250.
    >> Share

    March 2020
  411. BENNETSEN AKK, Baandrup L, Aalborg GL, Kjaer SK, et al
    Non-epithelial ovarian cancer in Denmark - Incidence and survival over nearly 40years.
    Gynecol Oncol. 2020 Mar 26. pii: S0090-8258(20)30246.
    >> Share

  412. GONZALEZ R, Gockley AA, Melamed A, Sugrue R, et al
    Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer.
    Gynecol Oncol. 2020 Mar 25. pii: S0090-8258(20)30228.
    >> Share

  413. RUSH SK, Swisher EM, Garcia RL, Pennington KP, et al
    Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Gynecol Oncol. 2020 Mar 19. pii: S0090-8258(20)30101.
    >> Share

  414. BETELLA I, Turbitt WJ, Szul T, Wu B, et al
    Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.
    Gynecol Oncol. 2020 Mar 16. pii: S0090-8258(20)30226.
    >> Share

  415. WOLFORD JE, Bai J, Moore KN, Kristeleit R, et al
    Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30176.
    >> Share

  416. LIONTOS M, Sotiropoulou M, Kaparelou M, Tzannis K, et al
    Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.
    Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30224.
    >> Share

  417. ROZE JF, Veldhuis WB, Hoogendam JP, Verheijen RHM, et al
    Prognostic value of radiological recurrence patterns in ovarian cancer.
    Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30219.
    >> Share

  418. VAN WALREE IC, Bretveld R, van Huis-Tanja LH, Louwers JA, et al
    Reasons for guideline non-adherence in older and younger women with advanced stage ovarian cancer.
    Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30221.
    >> Share

  419. LEVY T, Migdan Z, Aleohin N, Ben-Shem, et al
    Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome.
    Gynecol Oncol. 2020 Mar 6. pii: S0090-8258(20)30158.
    >> Share

  420. HAQUE R, Skates SJ, Armstrong MA, Lentz SE, et al
    Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations.
    Gynecol Oncol. 2020 Mar 4. pii: S0090-8258(20)30164.
    >> Share

  421. PIERSON WE, Peters PN, Chang MT, Chen LM, et al
    An integrated molecular profile of endometrioid ovarian cancer.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30144.
    >> Share

  422. GONTHIER C, Douhnai D, Koskas M
    Lymph node metastasis probability in young patients eligible for conservative management of endometrial cancer.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30157.
    >> Share

  423. REINHOLDT K, Kjaer SK, Guleria S, Frederiksen K, et al
    Risk of endometrial cancer among women with benign ovarian tumors - A Danish nationwide cohort study.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30178.
    >> Share

  424. MOORE KN, Zorn KK
    Germline and Somatic Testing in Ovarian Cancer: Shifting Sands of Recommendations.
    Gynecol Oncol. 2020;156:515-516.
    >> Share

  425. POWELL CB, Littell RD, Landen CN Jr, Pramanik S, et al
    Cytological sampling of fallopian tubes using a hysteroscopic catheter: A multi-center study.
    Gynecol Oncol. 2020;156:636-640.
    >> Share

  426. LENCK C, Chopin N, Gouy S, Bonsang-Kitzis H, et al
    The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
    Gynecol Oncol. 2020 Mar 1. pii: S0090-8258(20)30145.
    >> Share

    February 2020
  427. CHANG CP, Chen Y, Blackburn B, Abdelaziz S, et al
    Genitourinary disease risks among ovarian cancer survivors in a population-based cohort study.
    Gynecol Oncol. 2020 Feb 28. pii: S0090-8258(20)30162.
    >> Share

  428. PLETT H, Harter P, Ataseven B, Heitz F, et al
    Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors.
    Gynecol Oncol. 2020 Feb 27. pii: S0090-8258(20)30102.
    >> Share

  429. GLASER GE, Kalogera E, Kumar A, Yi J, et al
    Outcomes and patient perspectives following implementation of tiered opioid prescription guidelines in gynecologic surgery.
    Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30161.
    >> Share

  430. PRAISS AM, Huang Y, St Clair CM, Tergas AI, et al
    A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer.
    Gynecol Oncol. 2020 Feb 21. pii: S0090-8258(20)30150.
    >> Share

  431. O'MALLEY DM, Matulonis UA, Birrer MJ, Castro CM, et al
    Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2020 Feb 18. pii: S0090-8258(20)30090.
    >> Share

  432. UEHARA T, Yoshida H, Fukuhara M, Yoshida M, et al
    Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites.
    Gynecol Oncol. 2020 Feb 13. pii: S0090-8258(20)30099.
    >> Share

  433. FREY MK, Lee SS, Gerber D, Schwartz ZP, et al
    Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
    Gynecol Oncol. 2020 Feb 11. pii: S0090-8258(20)30007.
    >> Share

  434. PETERSEN S, Wilson AJ, Hirst J, Roby KF, et al
    CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
    Gynecol Oncol. 2020 Feb 7. pii: S0090-8258(20)30091.
    >> Share

  435. PIAO J, Lee EJ, Lee M
    Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30097.
    >> Share

  436. COLEMAN RL, Handley KF, Burger R, Molin GZD, et al
    Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30095.
    >> Share

  437. ROJAS C, Tian C, Powell MA, Chan JK, et al
    Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
    Gynecol Oncol. 2020 Feb 3. pii: S0090-8258(20)30057.
    >> Share

  438. SOLSKY I, Chen J, Rebbeck TR
    Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
    Gynecol Oncol. 2020;156:363-376.
    >> Share

  439. DOGAN NU, Dogan S, Erol M, Uzun BT, et al
    Cisterna chyli: An important landmark in laparoscopic paraaortic lymphadenectomy.
    Gynecol Oncol. 2020;156:511.
    >> Share

  440. VENERIS JT, Matulonis UA, Liu JF, Konstantinopoulos PA, et al
    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
    Gynecol Oncol. 2020;156:488-497.
    >> Share

    January 2020
  441. KORENAGA TR, Ward KK, Saenz C, McHale MT, et al
    The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30086.
    >> Share

  442. SIEMON J, Galli J, Slomovitz B, Schlumbrecht M, et al
    Disparities in care among patients with low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(19)31871.
    >> Share

  443. NASIOUDIS D, Mastroyannis SA, Latif NA, Ko EM, et al
    Trends in the surgical management of malignant ovarian germ-cell tumors.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30087.
    >> Share

  444. CABASAG CJ, Butler J, Arnold M, Rutherford M, et al
    Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study.
    Gynecol Oncol. 2020 Jan 28. pii: S0090-8258(19)31877.
    >> Share

  445. XUE C, Xu Y, Ye W, Xie Q, et al
    Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
    Gynecol Oncol. 2020 Jan 24. pii: S0090-8258(19)31804.
    >> Share

  446. STEWART LM, Stewart CJR, Spilsbury K, Cohen PA, et al
    Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma.
    Gynecol Oncol. 2020 Jan 23. pii: S0090-8258(20)30080.
    >> Share

  447. HAVRILESKY LJ, Lim S, Ehrisman JA, Lorenzo A, et al
    Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
    Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30070.
    >> Share

  448. BOGANI G, Ditto A, Lopez S, Bertolina F, et al
    Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Jan 21. pii: S0090-8258(19)31875.
    >> Share

  449. SLOMOVITZ B, Gourley C, Carey MS, Malpica A, et al
    Low-grade serous ovarian cancer: State of the science.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(19)31862.
    >> Share

  450. FEKETE JT, Osz A, Pete I, Nagy GR, et al
    Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(20)30006.
    >> Share

  451. CADOO KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, et al
    A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30060.
    >> Share

  452. NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
    Primary malignant ovarian carcinoid; management and outcomes.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30002.
    >> Share

  453. ACOSTA-TORRES S, Fader AN
    Laparoscopic splenectomy for secondary cytoreduction of ovarian cancer in a woman with localized splenic recurrence.
    Gynecol Oncol. 2020 Jan 16. pii: S0090-8258(19)31842.
    >> Share

  454. MERIDETH MA, Harney LA, Vyas N, Bachi A, et al
    Gynecologic and reproductive health in patients with pathogenic germline variants in DICER1.
    Gynecol Oncol. 2020 Jan 15. pii: S0090-8258(19)31867.
    >> Share

  455. GHIRARDI V, Moruzzi MC, Bizzarri N, Vargiu V, et al
    Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(20)30017.
    >> Share

  456. LLAURADO FERNANDEZ M, Dawson A, Kim H, Lam N, et al
    Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(19)31680.
    >> Share

  457. BEAVIS AL, Yen TT, Stone RL, Wethington SL, et al
    Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?
    Gynecol Oncol. 2020 Jan 13. pii: S0090-8258(19)31849.
    >> Share

  458. BIXEL K, Vetter M, Davidson B, Berchuck A, et al
    Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2020 Jan 11. pii: S0090-8258(19)31837.
    >> Share

  459. MORGAN RD, Banerjee S, Hall M, Clamp AR, et al
    Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30005.
    >> Share

  460. STALEY SA, Tucker K, Newton M, Ertel M, et al
    Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30003.
    >> Share

  461. RAFFONE A, Travaglino A, Mascolo M, Carotenuto C, et al
    Histopathological characterization of ProMisE molecular groups of endometrial cancer.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30008.
    >> Share

  462. WANG D, Zhu S, Jia C, Cao D, et al
    Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience.
    Gynecol Oncol. 2020 Jan 9. pii: S0090-8258(19)31872.
    >> Share

  463. MONK BJ, Herzog TJ, Wang G, Triantos S, et al
    A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Gynecol Oncol. 2020 Jan 8. pii: S0090-8258(19)31873.
    >> Share

  464. FRAUNE C, Rosebrock J, Simon R, Hube-Magg C, et al
    High homogeneity of MMR deficiency in ovarian cancer.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31861.
    >> Share

  465. SIAMAKPOUR-REIHANI S, Cobb LP, Jiang C, Zhang D, et al
    Differential expression of immune related genes in high-grade ovarian serous carcinoma.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31840.
    >> Share

  466. PEIRETTI M, Candotti G, Fais ML, Ricciardi E, et al
    Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31870.
    >> Share

  467. BREWER M, Angioli R, Scambia G, Lorusso D, et al
    Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
    Gynecol Oncol. 2020 Jan 6. pii: S0090-8258(19)31845.
    >> Share

  468. GORRINGE KL, Cheasley D, Wakefield MJ, Ryland GL, et al
    Therapeutic options for mucinous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 2. pii: S0090-8258(19)31836.
    >> Share

  469. VARGHESE A, Shih IM
    Not All Peritoneal Implants Are Created Equal.
    Gynecol Oncol. 2020;156:1-2.
    >> Share

  470. CHODAVADIA PA, Jacobs CD, Wang F, Havrilesky LJ, et al
    Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data.
    Gynecol Oncol. 2020;156:154-161.
    >> Share

  471. MHAWECH-FAUCEGLIA P, Izevbaye I, Spindler T, Wang G, et al
    Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature.
    Gynecol Oncol. 2020;156:6-12.
    >> Share

    December 2019
  472. SALMINEN L, Nadeem N, Jain S, Grenman S, et al
    A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
    Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31846.
    >> Share

  473. JORGE S, McFaddin AS, Doll KM, Pennington KP, et al
    Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
    Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31802.
    >> Share

  474. WAMBECKE A, Ahmad M, Lambert B, Joly F, et al
    The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
    Gynecol Oncol. 2019 Dec 26. pii: S0090-8258(19)31841.
    >> Share

  475. KAY AH, Venn M, Urban R, Gray HJ, et al
    Postoperative narcotic use in patients with ovarian cancer on an Enhanced Recovery After Surgery (ERAS) pathway.
    Gynecol Oncol. 2019 Dec 24. pii: S0090-8258(19)31839.
    >> Share

  476. JONES NL, Xiu J, Rocconi RP, Herzog TJ, et al
    Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
    Gynecol Oncol. 2019 Dec 24. pii: S0090-8258(19)31694.
    >> Share

  477. CONNOR YD, Miao D, Lin DI, Hayne C, et al
    Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
    Gynecol Oncol. 2019 Dec 21. pii: S0090-8258(19)31618.
    >> Share

  478. AREND RC, Davis AM, Chimiczewski P, O'Malley DM, et al
    EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low g
    Gynecol Oncol. 2019 Dec 20. pii: S0090-8258(19)31786.
    >> Share

  479. MATSUO K, Machida H, Matsuzaki S, Grubbs BH, et al
    Evolving population-based statistics for rare epithelial ovarian cancers.
    Gynecol Oncol. 2019 Dec 18. pii: S0090-8258(19)31781.
    >> Share

  480. NAUMANN RW, Coleman RL, Brown J, Moore KN, et al
    Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444].
    Gynecol Oncol. 2019 Dec 16. pii: S0090-8258(19)31799.
    >> Share

  481. KRILL L, Deng W, Eskander R, Mutch D, et al
    Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31795.
    >> Share

  482. NASIOUDIS D, Latif NA, Simpkins F, Cory L, et al
    Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31784.
    >> Share

  483. ZHANG H, Wu X, Xu Z, Sun Z, et al
    Impact of perioperative red blood cell transfusion on postoperative recovery and long-term outcome in patients undergoing surgery for ovarian cancer: A propensity score-matched analysis.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31798.
    >> Share

  484. PERES LC, Sinha S, Townsend MK, Fridley BL, et al
    Predictors of survival trajectories among women with epithelial ovarian cancer.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31803.
    >> Share

  485. ZHANG W, Tan C, Xu M, Wu X, et al
    Primary appendiceal mucinous neoplasm: Gynecological manifestations, management, and prognosis.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31681.
    >> Share

  486. KRIMMEL-MORRISON JD, Ghezelayagh TS, Lian S, Zhang Y, et al
    Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31783.
    >> Share

  487. RONCOLATO FT, O'Connell RL, Joly F, Lanceley A, et al
    Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(>/=3) chemotherapy - The GCIG symptom
    Gynecol Oncol. 2019 Dec 10. pii: S0090-8258(19)31558.
    >> Share

  488. VERGOTE I, Bergfeldt K, Franquet A, Lisyanskaya AS, et al
    A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.
    Gynecol Oncol. 2019 Dec 9. pii: S0090-8258(19)31685.
    >> Share

  489. GITTO SB, Kim H, Rafail S, Omran DK, et al
    An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
    Gynecol Oncol. 2019 Dec 6. pii: S0090-8258(19)31568.
    >> Share

  490. FORSSE D, Tangen IL, Fasmer KE, Halle MK, et al
    Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling.
    Gynecol Oncol. 2019 Dec 5. pii: S0090-8258(19)31782.
    >> Share

  491. HINCHCLIFF E, Jazaeri AA
    Sunset, or dawn of a new age for ovarian cancer vaccine therapy?
    Gynecol Oncol. 2019;155:387-388.
    >> Share

    November 2019
  492. VERGOTE I, Heitz F, Buderath P, Powell M, et al
    A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2019 Nov 29. pii: S0090-8258(19)31627.
    >> Share

  493. TAKAYA H, Nakai H, Sakai K, Nishio K, et al
    Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31664.
    >> Share

  494. NARASIMHULU DM, Bews KA, Hanson KT, Chang YH, et al
    Using evidence to direct quality improvement efforts: Defining the highest impact complications after complex cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31628.
    >> Share

  495. MATSUO K, Machida H, Grubbs BH, Matsuzaki S, et al
    Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31482.
    >> Share

  496. KIM J, Cho YJ, Ryu JY, Hwang I, et al
    CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
    Gynecol Oncol. 2019 Nov 24. pii: S0090-8258(19)31625.
    >> Share

  497. COLLINS A, Miles GJ, Wood J, MacFarlane M, et al
    Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer.
    Gynecol Oncol. 2019 Nov 22. pii: S0090-8258(19)31671.
    >> Share

  498. MAI PL, Huang HQ, Wenzel LB, Han PK, et al
    Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.
    Gynecol Oncol. 2019 Nov 21. pii: S0090-8258(19)31613.
    >> Share

  499. STASENKO M, Tunnage I, Ashley CW, Rubinstein MM, et al
    Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Gynecol Oncol. 2019 Nov 19. pii: S0090-8258(19)31615.
    >> Share

  500. LE PAGE C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, et al
    Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    Gynecol Oncol. 2019 Nov 18. pii: S0090-8258(19)31670.
    >> Share

  501. RODRIGUEZ-FREIXINOS V, Farinas-Madrid L, Gil-Martin M, Barretina-Ginesta P, et al
    Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277].
    Gynecol Oncol. 2019 Nov 16. pii: S0090-8258(19)31604.
    >> Share

  502. TAYLOR SE, Chu T, Elvin JA, Edwards RP, et al
    Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
    Gynecol Oncol. 2019 Nov 15. pii: S0090-8258(19)31616.
    >> Share

  503. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Learning curve of high-complexity surgery for advanced ovarian cancer.
    Gynecol Oncol. 2019 Nov 14. pii: S0090-8258(19)31621.
    >> Share

  504. GAGNO S, Poletto E, Bartoletti M, Quartuccio L, et al
    A TGF-beta associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
    Gynecol Oncol. 2019 Nov 8. pii: S0090-8258(19)31603.
    >> Share

  505. MOORE KN, Miller A, Bell-McGuinn KM, Schilder RJ, et al
    A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
    Gynecol Oncol. 2019 Nov 7. pii: S0090-8258(19)31569.
    >> Share

  506. ALIMUJIANG A, Khoja L, Wiensch A, Pike MC, et al
    "I am not a statistic" ovarian cancer survivors' views of factors that influenced their long-term survival.
    Gynecol Oncol. 2019 Nov 6. pii: S0090-8258(19)31564.
    >> Share

  507. FEHNIGER JE, Berger AA, Juckett L, Elvin J, et al
    Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.
    Gynecol Oncol. 2019 Nov 5. pii: S0090-8258(19)31561.
    >> Share

  508. CECERE SC, Giannone G, Salutari V, Arenare L, et al
    Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
    Gynecol Oncol. 2019 Nov 4. pii: S0090-8258(19)31607.
    >> Share

  509. BEIRNE JP, McArt DG, Roddy A, McDermott C, et al
    Defining the molecular evolution of extrauterine high grade serous carcinoma.
    Gynecol Oncol. 2019;155:305-317.
    >> Share

  510. ONG PY, Poon SL, Tan KT, Putti TC, et al
    Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
    Gynecol Oncol. 2019;155:275-279.
    >> Share

    October 2019
  511. O'CEARBHAILL RE, Deng W, Chen LM, Lucci JA 3rd, et al
    A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: A
    Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31536.
    >> Share

  512. ALLDREDGE J, Serna-Gallegos T, Gallegos N, VanLeer JP, et al
    Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival.
    Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31565.
    >> Share

  513. TATEBE K, Hasan Y, Son CH
    Adjuvant vaginal brachytherapy and chemotherapy versus pelvic radiotherapy in early-stage endometrial cancer: Outcomes by risk factors.
    Gynecol Oncol. 2019 Oct 11. pii: S0090-8258(19)31541.
    >> Share

  514. MARCHETTI C, Rosati A, Scaletta G, Pietragalla A, et al
    Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
    Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31545.
    >> Share

  515. BERG T, Nottrup TJ, Roed H
    Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31547.
    >> Share

  516. LABIDI-GALY SI, de La Motte Rouge T, Derbel O, Wolfer A, et al
    Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31528.
    >> Share

  517. KURODA T, Ogiwara H, Sasaki M, Takahashi K, et al
    Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31559.
    >> Share

    September 2019
  518. HOLLIS RL, Stanley B, Iida Y, Thomson J, et al
    Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
    Gynecol Oncol. 2019 Sep 5. pii: S0090-8258(19)31487.
    >> Share

  519. MAKII C, Ikeda Y, Oda K, Uehara Y, et al
    Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
    Gynecol Oncol. 2019 Sep 4. pii: S0090-8258(19)31480.
    >> Share

    August 2019
  520. MATSUO K, Cripe JC, Kurnit KC, Kaneda M, et al
    Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer.
    Gynecol Oncol. 2019 Aug 16. pii: S0090-8258(19)31458.
    >> Share

  521. KILTS TP, Glaser GE, Langstraat CL, Kumar A, et al
    Comparing risk stratification criteria for predicting lymphatic dissemination in endometrial cancer.
    Gynecol Oncol. 2019 Aug 10. pii: S0090-8258(19)31456.
    >> Share

  522. SALYER C, Kobelka C, Barrie A, Weintraub MR, et al
    Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.
    Gynecol Oncol. 2019;154:374-378.
    >> Share

    July 2019
  523. BARTELS HC, Rogers AC, McSharry V, McVey R, et al
    A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.
    Gynecol Oncol. 2019 Jul 23. pii: S0090-8258(19)31397.
    >> Share

  524. CYBULSKA P, Paula ADC, Tseng J, Leitao MM Jr, et al
    Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
    Gynecol Oncol. 2019 Jul 21. pii: S0090-8258(19)31398.
    >> Share

  525. HUBBARD AK, Poynter JN
    Global incidence comparisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988-2012.
    Gynecol Oncol. 2019 Jul 11. pii: S0090-8258(19)31348.
    >> Share

    June 2019
  526. XIANG M, English DP, Kidd EA
    Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
    Gynecol Oncol. 2019 Jun 27. pii: S0090-8258(19)31336.
    >> Share

  527. HENGEVELD EM, Zusterzeel PLM, Lajer H, Hogdall CK, et al
    The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2019 Jun 20. pii: S0090-8258(19)31317.
    >> Share

  528. TANG M, O'Connell RL, Amant F, Beale P, et al
    PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
    Gynecol Oncol. 2019 Jun 18. pii: S0090-8258(19)31322.
    >> Share

  529. DOTTINO JA, He W, Sun CC, Zhao H, et al
    Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes.
    Gynecol Oncol. 2019 Jun 14. pii: S0090-8258(19)31280.
    >> Share

  530. LIU JF, Gordon M, Veneris J, Braiteh F, et al
    Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
    Gynecol Oncol. 2019 Jun 13. pii: S0090-8258(19)31265.
    >> Share

  531. BERGAMINI A, Cormio G, Ferrandina G, Lorusso D, et al
    Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study.
    Gynecol Oncol. 2019 Jun 10. pii: S0090-8258(19)31273.
    >> Share

  532. FRAZER JL, Hook CE, Addley HC, Jackson CR, et al
    Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management.
    Gynecol Oncol. 2019 Jun 5. pii: S0090-8258(19)31277.
    >> Share

    May 2019
  533. NASIOUDIS D, Kahn R, Chapman-Davis E, Frey MK, et al
    Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31260.
    >> Share

  534. NASIOUDIS D, Haggerty AF, Giuntoli RL 2nd, Burger RA, et al
    Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma.
    Gynecol Oncol. 2019 May 30. pii: S0090-8258(19)31233.
    >> Share

  535. COHEN PA, Powell A, Bohm S, Gilks CB, et al
    Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Gynecol Oncol. 2019 May 19. pii: S0090-8258(19)31181.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016